BIOLOGICAL product claimed in patent or use of which claimed in patent before expiration of patent ; Statement described in subparagraph provided in connection with application to obtain license to engage in commercial manufacture, use or sale of
Index of Sec 2577. ...BIOLOGICAL product claimed in patent or use of which claimed in patent before expiration of patent ; Statement described in subparagraph provided in connection with application to obtain license to engage in commercial manufacture, use or sale of
Index of Sec 2577. ...PATENT ; Subparagraph, striking or
Index of Sec 2577. ...PATENT before expiration of patent ; Statement described in subparagraph provided in connection with application to obtain license to engage in commercial manufacture, use or sale of biological product claimed in patent or use of which claimed in
Index of Sec 2577. ...PATENT before expiration of patent ; Statement described in subparagraph provided in connection with application to obtain license to engage in commercial manufacture, use or sale of biological product claimed in patent or use of which claimed in
Index of Sec 2577. ...PATENT ; Statement described in subparagraph provided in connection with application to obtain license to engage in commercial manufacture, use or sale of biological product claimed in patent or use of which claimed in patent before expiration of
Index of Sec 2577. ...1st Session |
To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.
Mr. Dingell (for himself, Mr. Rangel, Mr. Waxman, Mr. George Miller of California, Mr. Stark, Mr. Pallone, and Mr. Andrews) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Government Reform, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
(a) Section 271(e)(2) of title 35, United States Code is amended—
(1) in subparagraph (A), by striking “or” after “patent,”;
(2) in subparagraph (B), by adding “or” after the comma at the end;
(3) by inserting the following after subparagraph (B):
“(C) a statement under section 351(l)(4)(D)(ii) of the Public Health Service Act,”; and
(4) in the matter following subparagraph (C) (as added by paragraph (3)), by inserting before the period the following: “, or if the statement described in subparagraph (C) is provided in connection with an application to obtain a license to engage in the commercial manufacture, use, or sale of a biological product claimed in a patent or the use of which is claimed in a patent before the expiration of such patent”.
(b) Section 271(e)(4) of title 35, United States Code, is amended by striking “in paragraph (2)” in both places it appears and inserting “in paragraph (2)(A) or (2)(B)”.